202 related articles for article (PubMed ID: 30859432)
21. Differences in Brain Glucose Metabolism During Preparation for
Jeong HS; Choi EK; Song IU; Chung YA; Park JS; Oh JK
Thyroid; 2017 Jan; 27(1):23-28. PubMed ID: 27774839
[TBL] [Abstract][Full Text] [Related]
22. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.
Kang JH; Jung DW; Pak KJ; Kim IJ; Kim HJ; Cho JK; Shin SC; Wang SG; Lee BJ
Head Neck; 2018 Jan; 40(1):94-102. PubMed ID: 29130586
[TBL] [Abstract][Full Text] [Related]
23. Comparison between remnant and red-marrow absorbed dose in thyroid cancer patients submitted to 131I ablative therapy after rh-TSH stimulation versus hypothyroidism induced by L-thyroxine withdrawal.
Vaiano A; Claudio Traino A; Boni G; Grosso M; Lazzeri P; Colato C; Davì MV; Francia G; Lazzeri M; Mariani G; Ferdeghini M
Nucl Med Commun; 2007 Mar; 28(3):215-23. PubMed ID: 17264781
[TBL] [Abstract][Full Text] [Related]
24. F-18 FDG PET/CT in the management of thyroid cancer.
Iagaru A; Kalinyak JE; McDougall IR
Clin Nucl Med; 2007 Sep; 32(9):690-5. PubMed ID: 17710020
[TBL] [Abstract][Full Text] [Related]
25. Thyroid-stimulating hormone-stimulated fused positron emission tomography/computed tomography in the evaluation of recurrence in 131I-negative papillary thyroid carcinoma.
Saab G; Driedger AA; Pavlosky W; McDonald T; Wong CY; Yoo J; Urbain JL
Thyroid; 2006 Mar; 16(3):267-72. PubMed ID: 16571089
[TBL] [Abstract][Full Text] [Related]
26. Comparison of whole-body 18F-FDG PET, 99mTc-MIBI SPET, and post-therapeutic 131I-Na scintigraphy in the detection of metastatic thyroid cancer.
Iwata M; Kasagi K; Misaki T; Matsumoto K; Iida Y; Ishimori T; Nakamoto Y; Higashi T; Saga T; Konishi J
Eur J Nucl Med Mol Imaging; 2004 Apr; 31(4):491-8. PubMed ID: 14666387
[TBL] [Abstract][Full Text] [Related]
27. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer.
Lind P; Kohlfürst S
Semin Nucl Med; 2006 Jul; 36(3):194-205. PubMed ID: 16762610
[TBL] [Abstract][Full Text] [Related]
28. Biochemical Markers Reflecting Thyroid Function in Athyreotic Patients on Levothyroxine Monotherapy.
Ito M; Miyauchi A; Hisakado M; Yoshioka W; Ide A; Kudo T; Nishihara E; Kihara M; Ito Y; Kobayashi K; Miya A; Fukata S; Nishikawa M; Nakamura H; Amino N
Thyroid; 2017 Apr; 27(4):484-490. PubMed ID: 28056660
[TBL] [Abstract][Full Text] [Related]
29. [F-18-fluordeoxyglucose positron emission tomography on patients with differentiated thyroid cancer who present elevated human serum thyroglobulin levels and negative I-131 whole body scan].
Ruiz Franco-Baux JV; Borrego Dorado I; Gómez Camarero P; Rodríguez Rodríguez JR; Vázquez Albertino RJ; Navarro González E; Astorga Jiménez R
Rev Esp Med Nucl; 2005; 24(1):5-13. PubMed ID: 15701340
[TBL] [Abstract][Full Text] [Related]
30. Positron emission tomography with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels, and negative iodine scans.
Altenvoerde G; Lerch H; Kuwert T; Matheja P; Schäfers M; Schober O
Langenbecks Arch Surg; 1998 Apr; 383(2):160-3. PubMed ID: 9641890
[TBL] [Abstract][Full Text] [Related]
31. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels.
Wang W; Macapinlac H; Larson SM; Yeh SD; Akhurst T; Finn RD; Rosai J; Robbins RJ
J Clin Endocrinol Metab; 1999 Jul; 84(7):2291-302. PubMed ID: 10404792
[TBL] [Abstract][Full Text] [Related]
32. Measurement of arterial activity on routine FDG PET/CT images improves prediction of risk of future CV events.
Figueroa AL; Abdelbaky A; Truong QA; Corsini E; MacNabb MH; Lavender ZR; Lawler MA; Grinspoon SK; Brady TJ; Nasir K; Hoffmann U; Tawakol A
JACC Cardiovasc Imaging; 2013 Dec; 6(12):1250-9. PubMed ID: 24269261
[TBL] [Abstract][Full Text] [Related]
33. F18-fluorodeoxyglucose positron emission tomography in detecting metastatic papillary thyroid carcinoma with elevated human serum thyroglobulin levels but negative I-131 whole body scan.
Hung MC; Wu HS; Kao CH; Chen WK; Changlai SP
Endocr Res; 2003 May; 29(2):169-75. PubMed ID: 12856803
[TBL] [Abstract][Full Text] [Related]
34. Value of diagnostic radioiodine whole-body scanning after initial therapy in patients with differentiated thyroid cancer at intermediate and high risk for recurrence.
Rosario PW; Furtado Mde S; Mineiro Filho AF; Lacerda RX; Calsolari MR
Thyroid; 2012 Nov; 22(11):1165-9. PubMed ID: 23050784
[TBL] [Abstract][Full Text] [Related]
35. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
[TBL] [Abstract][Full Text] [Related]
36. Intense 18-fluorodeoxyglucose uptake by the thymus on PET scan does not necessarily herald recurrence of thyroid carcinoma.
Godart V; Weynand B; Coche E; De Nayer P; Daumerie C
J Endocrinol Invest; 2005 Dec; 28(11):1024-8. PubMed ID: 16483183
[TBL] [Abstract][Full Text] [Related]
37. Utility of fluorine-18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels.
Muros MA; Llamas-Elvira JM; Ramírez-Navarro A; Gómez MJ; Rodríguez-Fernández A; Muros T; López de la Torre M; Becerra A; Carreras JL
Am J Surg; 2000 Jun; 179(6):457-61. PubMed ID: 11004330
[TBL] [Abstract][Full Text] [Related]
38. [(68)Ga]DOTATATE PET/MRI and [(18)F]FDG PET/CT are complementary and superior to diffusion-weighted MR imaging for radioactive-iodine-refractory differentiated thyroid cancer.
Vrachimis A; Stegger L; Wenning C; Noto B; Burg MC; Konnert JR; Allkemper T; Heindel W; Riemann B; Schäfers M; Weckesser M
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1765-72. PubMed ID: 27059853
[TBL] [Abstract][Full Text] [Related]
39. The incidence of thyroid cancer in focal hypermetabolic thyroid lesions: an 18F-FDG PET/CT study in more than 6000 patients.
Barrio M; Czernin J; Yeh MW; Palma Diaz MF; Gupta P; Allen-Auerbach M; Schiepers C; Herrmann K
Nucl Med Commun; 2016 Dec; 37(12):1290-1296. PubMed ID: 27612034
[TBL] [Abstract][Full Text] [Related]
40. Levothyroxine suppression of thyroglobulin in patients with differentiated thyroid carcinoma.
Wang PW; Wang ST; Liu RT; Chien WY; Tung SC; Lu YC; Chen HY; Lee CH
J Clin Endocrinol Metab; 1999 Dec; 84(12):4549-53. PubMed ID: 10599717
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
